A Novel SCN5A Variant Causes Temperature-Sensitive Loss Of Function in a Family with Symptomatic Brugada Syndrome, Cardiac Conduction Disease, and Sick Sinus Syndrome

Karolina Sanner a  Johanna Mueller-Leisse b  Christos Zormpas b  David Duncker b  Andreas Leffler a  Christian Veltmann b

a Department of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany; b Rhythmology and Electrophysiology, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

Keywords
Nav1.5 · Brugada syndrome · Channelopathy · Cardiac conduction disease

Abstract

Introduction: Brugada syndrome (BrS) is an inherited arrhythmia syndrome associated with an increased risk of sudden cardiac death. SCN5A is the most important disease-modifying gene for BrS, but many SCN5A variants have not been functionally characterized. Furthermore, the temperature dependency of SCN5A is only rarely explored in in vitro analyses. Methods: The clinical phenotype of the affected family was assessed by medical history, ECGs and ajmaline challenge. Whole-cell patch clamp recordings were performed on HEK 293T cells expressing Nav1.5-G1712S, a novel SCN5A variant found in the symptomatic family. Results: Three male family members had experienced sudden cardiac death, sudden cardiac arrest, and rhythmogenic syncope. Beside a positive ajmaline challenge with demarcation of a Brugada type 1 ECG, 1 patient also showed evidence of symptomatic cardiac conduction disease and sick sinus syndrome (SSS). In patch clamp analyses, Nav1.5-G1712S generated reduced peak currents as compared to the wild type. At body temperature, Nav1.5-G1712S additionally exhibited an enhanced slow inactivation and an impaired recovery from inactivation. Conclusion: We conclude that G1712S is a pathogenic SCN5A loss-of-function mutation at physiological temperature associated with an overlapping presentation of BrS, SSS, and cardiac conduction disease.

Introduction

Brugada syndrome (BrS) is an inherited arrhythmia syndrome associated with an increased risk of malignant cardiac arrhythmias. The variable phenotype of BrS makes an accurate individual risk stratification prior to the implementation of invasive preventive treatment options like an implantable cardioverter-defibrillator (ICD) or a pacemaker challenging [1]. Overlapping phenotypes with other inherited arrhythmia syndromes such as sick sinus syndrome (SSS), cardiac conduction disease, and long QT syndrome complicate the management of these patients [1, 2]. Genetic testing is being increasingly performed in symptomatic patients and their family members. A thorough understand-
standing of the pathogenicity of any given variant may lead to a more efficient risk stratification [1]. SCN5A encodes for the α-subunit of the cardiac sodium channel Nav1.5 and is probably the most relevant disease-modifying gene for BrS [3]. Variants of SCN5A are identified in about 20% of patients, but only some of them are actually considered causative [4, 5]. Typically, these variants associated with BrS display loss-of-function properties as determined by an in vitro patch clamp [1, 6]. These experiments are usually conducted at room temperature, which may be a critical limitation as some biophysical properties of sodium channels are temperature-sensitive [7–9]. We identified the SCN5A variant G1712S in a family with symptomatic BrS. This variant was already identified in a single patient with BrS [6], but it has not been characterized by means of in vitro electrophysiology, and no clinical data have been published. In this study, we present the phenotype of the affected family and biophysical properties of the mutant Nav1.5-G1712S.

**Materials and Methods**

**Clinical Analysis**

A family with BrS and familial sudden cardiac death was identified. All family members were encouraged to undergo complete clinical and genetic workup including medical and family history, physical examination, repetitive baseline ECGs, stress test, and ajmaline challenge. The study was approved by the Ethics Committee of Hannover Medical School (No. 1673-2013).

**Mutagenesis**

Human (h) Nav1.5 cDNA was PCR amplified and subcloned into the pTracer-SV40 vector (Invitrogen, Carlsbad, CA, USA). Nav1.5-G1712S and Nav1.5-G1712C mutants were generated by site-directed mutagenesis of hNav1.5 cDNA in pTracer-SV40 using the QuickChange Lightning Site-Directed Mutagenesis Kit (Agilent, Waldbronn, Germany) according to the instructions of the manufacturer. Mutants were sequenced to verify intended amino acid exchanges and to exclude further channel mutations.

**Cell Culture and Heterologous Expression**

All experiments were performed in accordance with the requirements of the local authorities (Gewerbeaufsicht, Niedersachsen, Germany). HEK 293T cells were cultured in standard Dulbecco’s modified Eagle medium (Gibco Life Technologies, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (Biochrom, Berlin, Germany), 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco Life Technologies, Karlsruhe, Germany) in a 37°C incubator in air with 5% CO₂. Wild-type hNav1.5, Nav1.5-G1712S, and Nav1.5-G1712C were transfected with JetPEI DNA Transfection Reagent (Polysplus-transfection, New York, NY, USA) using 3 µg of CDNA and 6 µg of JetPEI reagent. Patch Clamp recordings were performed within 72 h.

**Patch Clamp Experiments**

Na⁺ currents from transfected HEK 293T cells were recorded using the whole-cell configuration of the patch clamp technique with an HEKA EPC9 patch-clamp amplifier (HEKA Elektronik, Lambrecht, Germany). Data were sampled at 20 kHz and filtered at 5 kHz. Data were recorded using Pulse software (v 8.80; HEKA Elektronik) and analyzed with Fitmaster software (HEKA Elektronik, Lambrecht, Germany). Curve fitting and statistical analyses were performed using Origin 8.5 software (Microcal Software, Northampton, MA, USA). The bath solution contained (mM) 70 NaCl, 70 choline chloride, 3 KCl, 1 CaCl₂, 1 MgCl₂, 10 HEPES, and 15 glucose. pH was adjusted to 7.4 with tetraethylammonium hydroxide. The pipette solution contained (mM) 140 CsF, 10 NaCl, 10 HEPES, and 1 EGTA, pH 7.4 (CsOH). Pipettes were pulled from borosilicate glass (GB 100 TF-8P; Science Products, Berlin, Germany), and their resistance ranged from 1.0 to 2.5 MΩh. Serial resistance (5.2 ± 2.4 MΩhm) was compensated by 60–80% to minimize voltage errors. Capacitance artifacts were compensated using the amplifier circuitry. Patch clamp experiments were carried out at 22–24°C (room temperature) or at 35–37°C. For the experiments at physiological temperature, the external solution was preheated to 37°C, and during the experiments, the temperature was maintained using a heating plate filled with temperature-controlled solution.

**Statistical Analysis**

Clinical and electrophysiological data were presented as mean ± SD and mean ± SE, respectively. The χ² test and Fisher’s exact test were used for comparison of categorical variables. Statistical significance was calculated with one-way ANOVA with the post hoc Tukey test. A p value < 0.05 was considered statistically significant. Calculations were performed using Origin 8.5 (Microcal Software, Northampton, MA, USA). Data are presented as mean ± standard error of mean.

**Results**

**Family History**

The index patient (III-4, Fig. 1a, b) survived sudden cardiac arrest at the age of 11 months. The initial rhythm detected was ventricular fibrillation. The boy suffered severe brain damage after 1 h of cardiopulmonary resuscitation. The parents were asymptomatic, but the mother (II-2) had lost 2 pregnancies, and her father (I-1) had died of sudden cardiac arrest at the age of 38 years. The initial diagnostic workup of the boy (III-4) including echocardiography, repeat ECGs, and Holter ECG did not result in any diagnosis. Genetic testing revealed a heterozygous missense point mutation on SCN5A, leading to the exchange of a glycine (G) to serine (S) at position 1,712 (Gly1712Ser; 5134G>A). The same SCN5A variant was detected in the mother. After considering the family history and according to her personal wish, the mother received an ICD for primary prophylaxis. Two years later,
she gave birth to male twins. One was a stillborn, and the other (III-6) was born healthy but tested positive for SCN5A-G1712S. At the age of 3 years, the surviving twin suffered from a suspected rhythmogenic syncope during a febrile episode and received an ICD/pacemaker for secondary prophylaxis. After the ICD implantation, both patients (II-2 and III-6) have not experienced any recurrences of spontaneous arrhythmia nor any device-associated complications. No relevant clinical information was available from II-1 and his children.

Fig. 1. a Family pedigree with the index patient indicated by the red arrow. b Table giving clinical parameters of affected patients. SAB, spontaneous abortion; SCA, sudden cardiac arrest; #, no clinical data available. c, d Representative resting ECGs of III-6 (c, at the age of 7 years) and III-4 (d, at the age of 3 years). e Intrahospital ECG monitoring of III-6 after syncope.
Nav1.5-G1712S is a Variant of SCN5A Associated with Brugada Syndrome

Clinical Reassessment

At presentation in our outpatient clinic, we reviewed all clinical reports and ECGs available. While there were no pathological findings in the mother, several resting ECGs of her sons III-4 and III-6 were abnormal. In repeat ECGs, III-6 showed a sinus bradycardiac rhythm and prolonged PQ and QRS intervals for his age, with nonspecific depolarization and repolarization abnormalities (Fig. 1c). III-4 showed intermittent incomplete right bundle branch block with ST-elevations in V1 and V2 (Fig. 1d). Review of the emergency report of III-6 at the time of the syncope revealed the initial detected rhythm as bradycardia, with an escape rhythm of 40/min. Intra-hospital telemonitoring showed episodes of sinus bradycardia and a 2nd degree AV block (Fig. 1e). None of the reviewed ECGs showed a relevant prolongation or shortening of the QT interval. Due to the suspected familial channelopathy, we performed an ajmaline challenge in the mother. The test was positive with a Brugada type 1 ECG after administration of 35 mg of ajmaline (Fig. 2a), allowing the diagnosis of familial BrS. III-6 also produced a positive ajmaline (30 mg) test performed at the age of 11 years, for example, ajmaline induced coved-type ECG elevations in the right precordial leads. At the same time, he developed sinus arrest with stimulation of the ICD/ pacemaker (Fig. 2b). Taken together, we found the clinical manifestation of ventricular fibrillation in III-4, SSS as well as cardiac conduction disease in III-6, sudden cardiac death in I-1, and an asymptomatic phenotype in the only female variant carrier II-2.

In vitro Electrophysiology

We performed whole-cell patch clamp recordings on HEK-293T cells transiently expressing wild-type Nav1.5 or Nav1.5-G1712S. We also examined Nav1.5-G1712C, as a previous study described this BrS-associated variant as a loss-of-function mutation [10]. Currents were evoked in cells held at −120 mV and challenged with 100-ms-long voltage steps from −120 to +80 mV at room temperature (Fig. 3b). The peak current amplitudes were reduced for Nav1.5-G1712S (3.1 ± 0.7 nA, n = 20) as compared to Nav1.5-WT (8.3 ± 1.4 nA, n = 19, p < 0.01, unpaired t-test, Fig. 3c). Nav1.5-G1712C indeed displayed a complete loss-of-function phenotype (Fig. 3b, c). Identical experiments at physiological temperatures (e.g., 35–37°C) also gave smaller current amplitudes for Nav1.5-G1712S (3.1 ± 0.7 nA, n = 20) as compared to Nav1.5-WT (8.3 ± 1.4 nA, n = 19, p < 0.01, unpaired t-test, Fig. 3c). Nav1.5-G1712C indeed displayed a complete loss-of-function phenotype (Fig. 3b, c). Identical experiments at physiological temperatures (e.g., 35–37°C) also gave smaller current amplitudes for Nav1.5-G1712S (3.1 ± 0.7 nA, n = 20) as compared to Nav1.5-WT (8.3 ± 1.4 nA, n = 19, p < 0.01, unpaired t-test, Fig. 3c). However, the increase in temperature did not result in increased current amplitudes in any of the 2 constructs.
(\(p = 0.72\) for Nav1.5-WT and \(p = 0.45\) for Nav1.5-G1712S, unpaired \(t\)-tests). Plots of the current-voltage dependencies of Nav1.5-WT and Nav1.5-G1712S at both room and body temperature did not reveal any evident differences between Nav1.5-WT and Nav1.5-G1712S (Fig. 3f, g).

Moreover, no temperature-dependent effects on the voltage-dependent activation were observed (see online suppl. Fig. 1a,b; see www.karger.com/doi/10.1159/000518210 for all online suppl. material). The conversion of these current-voltage plots into normalized conductance did
Nav1.5-G1712S Is a Variant of SCN5A Associated with Brugada Syndrome

Fig. 4. a, b Steady-state fast inactivation plots for Nav1.5-WT (n = 18, respectively, 19) and Nav1.5-G1712S (n = 18 at both temperatures) recorded at room (a, 22–24°C) or near body (b, 35–37°C) temperature. Cells were held at −150 mV, and fast inactivation was induced by 100-ms-long depolarizing pulses followed by the test pulse at 0 mV (see inset). Mean data were normalized and fitted with the Boltzmann function. c, d Plots demonstrating recovery from fast inactivation of Nav1.5-WT (n = 22, respectively 25) and Nav1.5-G1712S (n = 18, respectively, 17) recorded at room (c, 22–24°C) or near body (d, 35–37°C) temperature. Cells were held at −150 mV, and slow inactivation was induced by 10-s-long depolarizing pulses followed by an interpulse at −150 mV allowing recovery from fast inactivation and the test pulse at 0 mV (see inset). Mean data were normalized, and a B-spline was drawn between data points to guide the eye. e, f Plots displaying voltage-dependent slow inactivation for Nav1.5-WT (n = 19, respectively, 9) and Nav1.5-G1712S (n = 13, respectively, 12) recorded at room (e, 22–24°C) or near body (f, 35–37°C) temperature. Cells were held at −150 mV, and slow inactivation was induced by 10-s-long depolarizing pulses followed by an interpulse at −150 mV allowing recovery from fast inactivation and the test pulse at 0 mV (see inset). Mean data were normalized, and a B-spline was drawn between data points to guide the eye. g, h, Plots demonstrating recovery from inactivation of Nav1.5-WT (n = 10, respectively, 11) and Nav1.5-G1712S (n = 11, respectively, 12) recorded at room (g, 22–24°C) or near body (h, 35–37°C) temperature. Cells were held at −150 mV, and inactivation was induced by a 10-s-long pre-pulse at 0 mV, followed by recovery at −150 mV for a variable duration before the test pulse to 0 mV was applied. Normalized data were fitted with a double exponential to obtain the time constants τ1 and τ2.

not reveal any differences between Nav1.5-WT (22–24°C: V0.5 = −47 ± 0.9 mV; 35–37°C: V0.5 = −49 ± 0.7 mV) and Nav1.5-G1712S (22–24°C: V0.5 = −48 ± 0.6 mV; 35–37°C: V0.5 = −47 ± 0.8 mV, Fig. 3h, i) or temperature-dependent effects (online suppl. Fig. 1c, d). The voltage-dependent fast inactivation was explored by applying 100-ms-long depolarizing pre-pulses ranging from −150 to −5 mV in steps of 5 mV, followed by a test pulse to 0 mV. Nav1.5-
WT and Nav1.5-G1712S displayed similar steady-state inactivation properties independent of temperature (room temperature WT: V0.5 = 96.7 ± 0.3 mV, Hill coefficient 6.9 ± 0.2, n = 18; G1712S: V0.5 = 99.4 ± 0.2 mV, Hill coefficient 7.8 ± 0.1, n = 18, Fig. 4a); body temperature: WT: V0.5 = 93.2 ± 0.4 mV, Hill coefficient 6.9 ± 0.2, n = 19; G1712S: V0.5 = 93.7 ± 0.5 mV, Hill coefficient 8.1 ± 0.3, n = 18, Fig. 4b). In both genotypes, the increase in temperature resulted in a discrete shift of the steady-state inactivation curve toward more depolarized potentials (online suppl. Fig. 1e, f). We next assessed the recovery from fast inactivation by applying a protocol consisting of two 20-ms-long consecutive pulses to −10 mV with a variable interval ranging from 0.1 to 1,683 ms. At room temperature, the time dependencies of recovery from fast inactivation were not significantly different for Nav1.5-WT (τ: 1.5 ± 0.1 ms, n = 22) and Nav1.5-G1712S (τ: 1.8 ± 0.1 ms, n = 18, p = 0.052 unpaired t-test, Fig. 4c). At 35–37°C however, the time course for recovery from fast inactivation was slower for Nav1.5-G1712S (τ: 1.3 ± 0.08 ms, n = 25) than Nav1.5-WT (τ: 0.6 ± 0.04 ms, n = 17, p < 0.05 unpaired t-test, Fig. 4d). Thus, the increase in temperature revealed a robust phenotype of Nav1.5-G1712S in case of recovery from inactivation. While both Nav1.5-WT (p < 0.001, unpaired t-test, online suppl. Fig. 1g) and Nav1.5-G1712S (p < 0.01, unpaired t-test, online suppl. Fig. 1h) recovered significantly faster upon heating, this effect seemed to be more robust on Nav1.5-WT than Nav1.5-G1712S. We next explored the voltage dependency of slow inactivation, which was induced by 10 s long depolarizing pulses ranging from −150 to 0 mV. Before the test pulse to 0 mV was applied, a 20-ms-long inter-pulse at −150 mV was inserted to allow recovery from fast inactivation. Both genotypes displayed incomplete slow inactivation with this protocol (Fig. 4e), making the calculation of the midpoint of slow-inactivation impossible. However, the fractions of inactivated channels after the final inactivating pulse to 0 mV were similar for Nav1.5-WT (45 ± 4%, n = 19) and Nav1.5-G1712S (45 ± 5%, n = 13, p = 0.98 unpaired t-test). At body temperature however, the remaining fraction of available channels was larger for Nav1.5-WT (60 ± 3%, n = 9) than for Nav1.5-G1712S (42 ± 4%, n = 12, p < 0.01, unpaired t-test, Fig. 4f). Again, this emerging phenotype at body temperature was explained by the fact that Nav1.5-WT (p < 0.05, unpaired t-test, online suppl. Fig. 1i) but not Nav1.5-G1712S (p = 0.56, unpaired t-test, online suppl. Fig. 1j) displayed less slow inactivation at 35–37°C than at 22–24°C. We finally applied a protocol examining recovery from both fast and slow inactivation. In cells held at −150 mV, at 10-s-long pre-pulse was applied to fully inactivate the channels. Following recovery at −150 mV during a variable time (1–16,384 ms), available channels were assessed by a test pulse to 0 mV. Both genotypes displayed a biphasic recovery from inactivation (Fig. 3g, h). When best fitted with a double exponential function, the two time constants τ1 and τ2 were calculated to Nav1.5-WT: τ1: 6.3 ± 2.1 ms, τ2: 99.7 ± 15.4 ms (n = 10), and Nav1.5-G1712S: τ1: 8.3 ± 1.9 ms, τ2: 155.6 ± 19.7 ms (n = 11) when explored at room temperature. While τ1 was not significantly different (p = 0.99), τ2 was significantly slower for Nav1.5-G1712S than for Nav1.5-WT (p < 0.019) (ANOVA one-way with Tukey post hoc test). At 35–37°C, Nav1.5-G1712S (τ1: 11.2 ± 2.7 ms, τ2: 141.0 ± 16.6 ms, n = 12) exhibited a slower recovery than Nav1.5-WT (τ1: 3.9 ± 0.6 ms, τ2: 77.2 ± 12.2 ms, n = 11). This difference was not significant for τ1 (p = 0.96), but for τ2 (p < 0.001) (ANOVA one-way with Tukey post hoc test).

**Discussion**

We identified the missense mutation G1712S in SCN5A in a family with symptomatic BrS and found that the mutation causes a loss-of-function as Nav1.5-G1712S generated smaller inward currents than Nav1.5-WT. Surprisingly, an enhanced slow inactivation and an impeded recovery from fast and slow inactivation of Nav1.5-G1712S became evident only when experiments were conducted at physiological temperatures. Thus, the mere analysis at room temperature may have promoted misinterpretation of Nav1.5-G1712S as a polymorphism with a more modest loss-of-function phenotype. In fact, similar biophysical properties have been proposed as pathogenic for other Brugada-causing Nav1.5 mutations [2, 9]. Together with the clinical information and previously published in silico analysis, Nav1.5-G1712S can be declared as a pathogenic mutation with high probability to cause BrS as well as possibly SSS and cardiac conduction disease [5].

G1712S was previously reported to be associated with a Brugada phenotype in a single patient, and an in silico analysis had proposed a likely pathogenicity. However, that report lacked both clinical data and an electrophysiologial characterization [6]. In fact, around 10% of published Brugada-associated SCN5A variants are suspected to be nonpathogenic [4]. The observation that some patients with a BrS phenotype completely lack Nav1.5-mutations has raised questions about the relevance of Nav1.5 mutations as causative for BrS [11]. This notion is sup-
Nav1.5-G1712S is a Variant of SCN5A Associated with Brugada Syndrome

DOI: 10.1159/000518210

Conclusions

Taken together, we characterized a new pathogenic SCN5A mutation, G1712S. It was associated with symptomatic BrS, cardiac conduction disease, and SSS requiring pacemaker therapy. The mutant caused a loss-of-function phenotype, but some effects were only obvious at physiological temperatures. Together with previous reports, our data suggest that reliable functional studies should be carried out at physiological temperature in addition to room temperature. Moreover, our findings stress the relevance of overlap syndromes and bradycardia in patients with BrS.
Acknowledgements

The authors thank Kerstin Reher, Marina Golombek, and Heike Bürger (Department of Anesthesiology) for excellent technical assistance.

Statement of Ethics

The study conforms to the Declaration of Helsinki. The study was approved by the Ethics Committee of Hannover Medical School (No. 1673-2013). The requirement of informed consent for this study was waived by the Institutional Committee on Human Research.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

References

1. Antzelevitch C, Yan GX, Ackerman MJ, Borggreve M, Corrado D, Guo J, et al. J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. J Arrhythm. 2016;32(5):315–39.
2. Veltmann C, Barajas-Martínez H, Wolpert C, Borggreve M, Schimpf R, Pfeiffer R, et al. Further insights in the most common SCNSA mutation causing overlapping phenotype of long QT syndrome, Brugada syndrome, and conduction defect. J Am Heart Assoc. 2016;5:e003379.
3. Hosseini SM, Kim R, Udupa S, Costain G, Jobling R, Liston E, et al. Rep appraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for Brugada syndrome. Circulation. 2018;138:1195–205.
4. Rigaard B, Jabbari R, Refsgaard L, Holst AG, Haunso S, Sadjadieh A, et al. High prevalence of genetic variants previously associated with Brugada syndrome in new exome data. Clin Genet. 2013;84:489–95.
5. Campuzano O, Allegue C, Fernandez A, Iglesias A, Brugada R. Determining the pathogenicity of genetic variants associated with cardiac channelopathies. Sci Rep. 2015;5:7953.
6. Kapplinger JD, Tester DJ, Alders M, Benito B, Nesterenko DV, Nesterenko VV, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res. 1999;85:803–9.
7. Amin AS, Verkerk AO, Bhuiyan ZA, Wilde AA, Tan HL. Novel Brugada syndrome-causing mutation in ion-conducting pore of cardiac Na+ channel does not affect ion selectivity properties. Acta Physiol Scand. 2005;185:291–301.
8. Chen YY, Liu SR, Xie LZ, Zhu TY, Chen YZ, Deng XI, et al. Functional analysis of a novel SCNSA mutation G1712C identified in Brugada syndrome. Nan Fang Yi Ke Da Xue Xue Bao. 2016;37:256–60.
9. Probst V, Wilde AA, Barc J, Sacher F, Babuty D, Mabo P, et al. SCNSA mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet. 2009;2:552–7.
10. Bezina CR, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, et al. Common variants at SCNSA-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013;45:1049–49.
11. Savio-Galimberti E, Argenziano M, Antzelevitch C. Cardiac arrhythmias related to sodium channel dysfunction. Handb Exp Pharmacol. 2018;246:331–54.
12. Li Z, Jin X, Wu T, Zhao X, Wang W, Lie J, et al. Structure of human Na v 1.5 reveals the fast inactivation-related segments as a mutational hotspot for the long QT syndrome. Proc Natl Acad Sci USA. 2021;116(1):118.
13. Ong BH, Tomaselli GF, Balse R, et al. Structural rearrangement in the sodium channel pore linked to slow inactivation and use dependence. J Gen Physiol. 2000;116:653–62.
14. DeMarco KR, Clancy CE. Cardiac Na channels: structure to function. Curr Top Membr. 2016;78:287–311.
15. Patton DE, West JW, Catterall WA, Goldin AL. Amino acid residues required for fast Na(+) channel inactivation: charge neutralizations and deletions in the III–IV linker. Proc Natl Acad Sci U S A. 1992;89:10905–9.
16. Probst V, Wilde AA, Barc J, Sacher F, Babuty D, Mabo P, et al. SCNSA mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet. 2009;2:552–7.
17. Nesterenko DV, Nesterenko VV, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res. 1999;85:803–9.
18. Meregalli PG, Tan HL, Probst V, Koopmann TT, Tzanck MW, Bhuiyan ZA, et al. Type of SCNSA mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm. 2009;6:314–8.
19. Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007;115:2481–9.
20. Morita H, Fukushima-Kusano K, Nagase S, Miyaji K, Hiramatsu S, Banba K, et al. Sinus node function in patients with Brugada-type ECG. J Clin. 2004;68:473–6.
21. Raviele A, Di Pedre F, Zanocco A, Zuin G, Facin G, Mazzaro I, et al. [Predictive value of the ajmaline test in dysfunction of the sinus node. Prospective 4-year follow-up relative to 77 patients]. G Ital Cardiol. 1985;15:751–60.
22. van den Berg MP, Wilde AA, Vietsma TJW, Brouwer J, Haaksma J, van der Hout AH, et al. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol. 2001;12:630–6.
23. Abe K, Machida T, Sumimoto N, Yamamoto H, Ohkubo K, Watanabe I, et al. Sodium channelopathy underlying familial sick sinus syndrome with early onset and predominantly male characteristic. Circ Arrhythm Electrophysiol. 2014;7:511–7.
24. Makiyama T, Akao M, Tsuji K, Doi T, Ohno S, Takenaka K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCNSA gene mutations. J Am Coll Cardiol. 2005;46:2100–6.